Compare Novo Nordisk A/S (NVO) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Orion Office REIT Inc — how do they compare? Novo Nordisk A/S trades at $46.32 (market cap $207.85B), while Orion Office REIT Inc trades at $2.78 (market cap $158.01M). The key difference: Novo Nordisk A/S is far larger — about 1315.4× Orion Office REIT Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | ONL | |
|---|---|---|
Market Cap | $207.85B | $158.01M |
Sector | Health | Real Estate |
52-Week High | $63.98 | $3.04 |
52-Week Low | $35.29 | $1.93 |
Enterprise Value | $222.55B | $574.95M |
Dividend Yield | 3.81% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
ONL trades at $2.83, up 2.91% with a bullish technical signal and strong moving average support. The company reported mixed Q2 2026 results with an EPS beat but continues to face fundamental challenges including declining revenue from $208M in 2022 to $148M in 2025 and negative net margins. Recent news highlights strategic review progress and portfolio repositioning efforts.
The outlook remains cautious despite technical strength. While the stock shows bullish momentum and pays consistent dividends, persistent revenue declines, negative profitability metrics, and high debt levels pose significant risks. Analyst sentiment is evenly split between Buy and Hold recommendations, reflecting uncertainty about the company's turnaround strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
